Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2016), Target Oncol, 11, 557 - 563
Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial
Harrington K. et al, (2016), MELANOMA RESEARCH, 26, E4 - E5
Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka R. et al, (2016), MELANOMA RESEARCH, 26, E36 - E37
PREDICTING PATHOLOGICAL RESPONSE OF ESOPHAGEAL CANCER TO NEOADJUVANT CHEMOTHERAPY: THE IMPLICATIONS OF METABOLIC NODAL RESPONSE FOR PERSONALISED THERAPY
Findlay JM. et al, (2016), Journal of Nuclear Medicine
Delayed oral toxicity from BRAF-targeted therapy
Lloyd-Lavery A. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 24 - 24
Durable response rates with talimogene laherparepvec or granulocyte-macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB-IVM1a melanoma in the OPTiM trial
Harrington K. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 73 - 73
Erratum to: Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.
Findlay JM. et al, (2016), Dig Dis Sci, 61
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR. et al, (2016), Cancer Med, 5, 1436 - 1443
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J. et al, (2016), Targeted oncology, 11, 401 - 415
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
Plummer ER. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Real-world overall survival in advanced melanoma from the IMAGE study.
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Middleton MR. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo J. et al, (2016), Targeted Oncology
PREFERENCE-BASED UTILITIES FOR ADJUVANT MELANOMA IN THE UNITED KINGDOM AND AUSTRALIA
Middleton M. et al, (2016), VALUE IN HEALTH, 19, A157 - A157
TREATMENT PATTERNS AMONG ADVANCED MELANOMA PATIENTS IN EUROPE
Sheahan K. et al, (2016), VALUE IN HEALTH, 19, A162 - A162
Durable response of spinal chordoma to combined inhibition of IGF-1R and EGFR
Macaulay V. et al, (2016), Frontiers in Oncology
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.
Findlay JM. et al, (2016), Nature communications, 7, 11111 - 11111
Phase I Dose Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Macaulay V., (2016), Clinical Cancer Research
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.
Blagden SP. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34